Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.

Trial Profile

Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms RAPIDA
  • Sponsors AbbVie
  • Most Recent Events

    • 01 Nov 2017 Results evaluating the rapidity of onset of clinical response to ADA therapy presented at the 25th United European Gastroenterology Week
    • 10 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top